Artiva Biotherapeutics, Inc. Stock-Based Compensation
Artiva Biotherapeutics, Inc. (ARTV) reported Stock-Based Compensation of $3.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.86M, a 20.40% increase year-over-year.
- Artiva Biotherapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.59M, a 22.37% decline year-over-year.
- Artiva Biotherapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.59M, a 27.24% decline year-over-year.
- Artiva Biotherapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.63M, a 14.47% decline year-over-year.
- Artiva Biotherapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $6.82M, a 2.28% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.98M, a 1.04% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $7.05M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.46M 10-Q · filed 2026-08-06 | $5.05M derived: sum of 3 quarters · filed 2026-08-06 | $6.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.59M 10-Q · filed 2026-05-08 | $3.18M derived: sum of 2 quarters · filed 2026-05-08 | $4.81M derived: sum of 3 quarters · filed 2026-05-08 | $6.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $3.22M derived: sum of 2 quarters · filed 2026-03-10 | $4.77M derived: sum of 3 quarters · filed 2026-08-06 | $6.82M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.18M derived: sum of 2 quarters · filed 2026-08-06 | $5.23M 10-Q · filed 2025-11-12 | $7.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.60M 10-Q · filed 2026-08-06 | $5.79M derived: sum of 3 quarters · filed 2026-08-06 | $7.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.05M 10-Q · filed 2026-05-08 | $4.24M derived: sum of 2 quarters · filed 2026-05-08 | $6.14M derived: sum of 3 quarters · filed 2026-05-08 | $7.63M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $4.09M derived: sum of 2 quarters · filed 2026-03-10 | $5.57M derived: sum of 3 quarters · filed 2026-03-10 | $6.98M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.39M derived: sum of 2 quarters · filed 2025-11-12 | $4.80M 10-Q · filed 2025-11-12 | $6.19M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.89M 10-Q · filed 2025-08-06 | $4.28M derived: sum of 3 quarters · filed 2025-08-06 | $5.65M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.41M 10-Q · filed 2025-05-08 | $2.80M derived: sum of 2 quarters · filed 2025-05-08 | $4.17M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.76M derived: sum of 2 quarters · filed 2025-03-24 | $7.05M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.66M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $4.29M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |